12/29
06:06 am
idya
In This Article : [Yahoo! Finance]
Low
Report
In This Article : [Yahoo! Finance]
12/29
06:00 am
idya
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
Low
Report
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
12/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/17
09:23 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/17
08:35 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
12/17
06:10 am
idya
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
Low
Report
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma [Yahoo! Finance]
12/17
06:00 am
idya
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
Low
Report
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma
12/16
06:00 am
idya
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
Low
Report
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
12/16
05:59 am
idya
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years [Yahoo! Finance]
Low
Report
IDEAYA Biosciences (NASDAQ:IDYA) pulls back 9.2% this week, but still delivers shareholders solid 23% CAGR over 5 years [Yahoo! Finance]
12/11
06:17 am
idya
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 [Yahoo! Finance]
Medium
Report
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 [Yahoo! Finance]
12/11
06:00 am
idya
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
Medium
Report
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024
12/10
06:02 am
idya
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer [Yahoo! Finance]
Low
Report
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer [Yahoo! Finance]
12/10
06:00 am
idya
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
Low
Report
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
12/9
06:12 am
idya
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor [Yahoo! Finance]
12/9
06:00 am
idya
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
Low
Report
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor
12/6
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/2
06:00 am
idya
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
Low
Report
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events
11/29
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/26
07:05 am
idya
Hexagon Bio Appoints Yujiro Hata to Board of Directors [Yahoo! Finance]
Low
Report
Hexagon Bio Appoints Yujiro Hata to Board of Directors [Yahoo! Finance]
11/22
07:49 am
idya
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
Low
Report
Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts [Yahoo! Finance]
11/18
08:50 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
11/18
06:10 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
11/18
06:00 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
11/12
06:00 am
idya
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Medium
Report
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
11/11
06:00 am
idya
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Low
Report
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise